Abbott Will “Actively Promote” Synthroid Despite Generic Entrants
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will not cease marketing efforts in the face of AB-rated levothyroxine generics from Mylan and Sandoz. U.S. Synthroid sales jumped 24% during the quarter due to increased share and favorable year-over-year comparisons.